Synergistic cytotoxicity of artemisinin and sodium butyrate on human cancer cells

Anticancer Research

Volumn 25, Issue 6 B, 2005, Pages 4325-4331

  Singh, Narendra P ^a   Lai, Henry C ^a  

^a University of Washington   (United States)

Author keywords

Artemisinin; Butyric acid; Lymphocytes; Molt 4 cells

Indexed keywords

ANTIINFLAMMATORY AGENT; ARTEMISIA ANNUA EXTRACT; ARTEMISININ; ARTEMISININ DERIVATIVE; BUTYRIC ACID; CARBON DIOXIDE; DIHYDROARTEMISININ; HOLOTRANSFERRIN; IRON; SHORT CHAIN FATTY ACID; TRANSFERRIN; UNCLASSIFIED DRUG;

APOPTOSIS; ARTEMISIA ANNUA; ARTICLE; CANCER CELL; CELL COUNT; CELL KILLING; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG EFFICACY; DRUG POTENTIATION; DRUG SELECTIVITY; HUMAN; HUMAN CELL; IN VITRO STUDY; INTESTINE FLORA; LYMPHOCYTE COUNT; NUTRIENT; PRIORITY JOURNAL;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; ARTEMISININS; BUTYRATES; CELL LINE, TUMOR; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG SYNERGISM; HUMANS; LYMPHOCYTES; SESQUITERPENES;

EID: 27944491872     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (46)

1. Li Y and Wu YL: An over four millennium story behind ginghaosu (artemisinin) - a fantastic antimalarial drug from a traditional Chinese herb. Curr Med Chem 10: 2197-2230, 2003.
2. Karin M and Mintz B: Receptor-mediated endocytosis of transferrin in developmentally totipotent mouse teratocarcinoma stem cells. J Biol Chem 256: 3245-3252, 1981.
3. May WS and Cuatrecasas P: Transferrin receptor: its biological significance. J Membr Biol 88: 205-215, 1985.
4. Lai H and Singh NP: Selective cancer cell cytotoxicity from exposure to dihydroartemisinin and holotransferrin. Cancer Lett 91: 41-46, 1995.
5. Moore JC, Lai H, Li J, McDougall JA, Singh NP and Chou CK: Oral administration of dihydroartemisinin and ferrous sulfate retarded implanted fibrosarcoma growth in the rat. Cancer Lett 98: 83-87, 1995.
6. Singh NP and Lai H: Selective toxicity of dihydroartemisinin and holotransferrin toward human breast cancer cells. Life Sciences 70: 49-56, 2001.
7. Singh NP and Verma KB: Case report of a laryngeal squamous cell carcinoma treated with artesunate. Archive Oncol 10: 279-280, 2002.
8. Sun WC, Han JX, Yang WY, Deng DA and Yue XF: Antitumor activities of 4 derivatives of artemisic acid and artemisinin B in vitro. Chung KuoYao Li Hsueh Pao 13: 541-543, 1995.
9. Efferth T, Dunstan H, Sauerbrey A, Miyachi H and Chitambar CR: The antimalarial artesunate is also active against cancer. Int J Oncol 18: 767-783, 2001.
10. Singh NP and Lai H: Artemisinin induces apoptosis in human cancer cells. Anticancer Res 24: 2277-2280, 2004.
11. Yamachika E, Habte T and Oda D: Artemisinin: an alternative treatment for oral squamous cell carcinoma. Anticancer Res 24: 2153-2160, 2004.
12. Cummings JH: Short chain fatty acids in the human colon. Gut 22: 763-779, 1981.
13. D'Argenio G and Mazzacca G: Short-chain fatty acid in the human colon. Relation to inflammatory bowel diseases and colon cancer. Adv Exp Med Biol 472: 149-158, 1999.
14. Wollowski I, Rechkemmer G and Pool-Zobel BL: Protective role of probiotics and prebiotics in colon cancer. Am J Clin Nutr 73(2 Suppl): 451S-455S, 2001.
15. Roediger WE: Role of anaerobic bacteria in the metabolic welfare of the colonic mucosa in man. Gut 21: 793-798, 1980.
16. Treptow-van Lishaut S, Rechkemmer G, Rowland I, Dolara P and Pool-Zobel BL: The carbohydrate crystalean and colonic microflora modulate expression of glutathione S-transferase subunits in colon of rats. Eur J Nutr 38: 76-83, 1999.
17. Leng SL, Leeding KS, Gibson PR and Bach LA: Insulin-like growth factor-II renders LIM 2405 human colon cancer cells resistant to butyrate-induced apoptosis: a potential mechanism for colon cancer cell survival in vivo. Carcinogenesis 22: 1625-1631, 2001.
18. Velazquez OC, Jabbar A, DeMatteo RP and Rombeau JL: Butyrate inhibits seeding and growth of colorectal metastases to the liver in mice. Surgery 120: 440-447, 1996.
19. Hass R, Busche R, Luciano L, Reale E and Engelhardt WV: Lack of butyrate is associated with induction of Bax and subsequent apoptosis in the proximal colon of guinea pig. Gastroenterology 772: 875-881, 1997.
20. Medina V, Afonso JJ, Alvarez-Arguelles H, Hernandez C and Gonzalez F: Sodium butyrate inhibits carcinoma development in a 1,2-dimethylhydrazine- induced rat colon cancer. J Parenter Enteral Nutr 22: 14-17, 1998.
21. Kuefer R, Hofer MD, Altug V, Zorn C, Genze F, Kunzi-Rapp K, Hautmann RE and Gschwend JE: Sodium butyrate and tributyrin induce in vivo growth inhibition and apoptosis in human prostate cancer. Br J Cancer 90: 535-541, 2004.
22. Scheppach W, Bartram HP and Richter F: Role of short-chain fatty acids in the prevention of colorectal cancer. Eur J Cancer 31A: 1077-1080, 1995.
23. Rephaeli A, Rabizadeh E, Aviram A, Shaklai M, Ruse M and Nudelman A: Derivatives of butyric acid as potential anti-neoplastic agents. Int J Cancer 49: 66-72, 1991.
24. Miller AA, Kurschel E, Osieka R and Schmidt CG: Clinical pharmacology of sodium butyrate in patients with acute leukemia. Eur J Cancer Clin Oncol 23: 1283-1287, 1987.
25. Rozental R, Faharani R, Yu Y, Johnson JM, Chan SO and Chiu FC: Sodium butyrate induces apoptosis in MSN neuroblastoma cells in a calcium independent pathway. Neurochem Res 29: 2125-2134, 2004.
26. Rabizadeh E, Bairey O, Aviram A, Ben-Dror I, Shaklai M and Zimra Y: Doxorubicin and a butyric acid derivative effectively reduce levels of BCl-2 protein in the cells of chronic lymphocytic leukemia patient. Eur J Haematol 66: 263-271, 2001.
27. Rephaeli A, Blank-Porat D, Tarasenko N, Entin-Meer M, Levovich I, Cutts SM, Phillips DR, Malik Z and Nudelman A: In vivo and in vitro antitumor activity of butyroyloxymethyldiethyl phosphate (AN-7), a histone deacetylase inhibitor, in human prostate cancer. Int J Cancer, 2005 (Epub ahead of print).
28. Gleave ME, Sato N, Sadar M, Yago V, Bruchovsky N and Sullivan L: Butyrate analogue, isobutyramide, inhibits tumor growth and time to androgen-independent progression in the human prostate LNCaP tumor model. J Cell Biochem 69: 271-281, 1998.
29. Boyum A: Isolation of mononuclear cells and granulocytes from human blood. Scand J Clin Lab Invest 97(suppl): 77-89, 1968.
30. Vidali G, Boffa LC, Bradbury EM and Allfrey VG: Butyrate suppression of histone deacetylation leads to accumulation of multiacetylated forms of histones H3 and H4 and increased DNase I sensitivity of the associated DNA sequences. Proc Natl Acad Sci USA 75: 2239-2243, 1978.
31. Hague A, Manning AM, Hanlon KA, Huschtscha LI, Hart D and Paraskeva C: Sodium butyrate induces apoptosis in human colonie tumour cell lines in a p53-independent pathway: implications for the possible role of dietary fibre in the prevention of large-bowel cancer. Int J Cancer 55: 498-505, 1993.
32. Carducci MA, Nelson JB, Chan-Tack KM, Ayyagari SR, Sweatt WH, Campbell PA, Nelson WG and Simons JW: Phenylbutyrate induces apoptosis in human prostate cancer and is more potent than phenylacetate. Clin Cancer Res 2: 379-387, 1996.
33. Feinman R, Clarke KO and Harrison LE: Phenylbutyrate-induced apoptosis is associated with inactivation of NF-kappaB in HT-29 colon cancer cells. Cancer Chemother Pharmacol 49: 27-34, 2002.
34. Jung M: Inhibitors of histone deacetylase as new anticancer agents. Curr Med Chem 8: 1505-1511, 2001.
35. Andoh A, Bamba T and Sasaki M: Physiological and anti-inflammatory roles of dietary fiber and butyrate in intestinal functions. J Parenter Enteral Nutr 23(5 Suppl): S70-S73, 1999.
36. Patz J, Jacobsohn WZ, Gottschalk-Sabag S, Zeides S and Braverman DZ: Treatment of refractory distal ulcerative colitis with short chain fatty acid enemas. Am J Gastroenterol 91: 731-734, 1996.
37. Steinhart AH, Brzezinski A and Baker JP: Treatment of refractory ulcerative proctosigmoiditis with butyrate enemas. Am J Gastroenterol 89: 179-183, 1994.
38. Venkatraman A, Ramakrishna BS, Shaji RV, Kumar NS, Pulimood A and Patra S: Amelioration of dextran sulfate colitis by butyrate: role of heat shock protein 70 and NF-kappaB. Am J Physiol Gastrointest Liver Physiol 28: G177-G184, 2003.
39. Rouault TA, Hentze MW, Dancis A, Caughman W, Harford JB and Klausner RD: Influence of altered transcription on the translational control of human ferritin expression. Proc Natl Acad Sci USA 84: 6335-6339, 1987.
40. Kawasaki N, Morimoto K and Hayakawa T: Control of hemoglobin synthesis in erythroid differentiating K562 cells. II. Studies of iron mobilization in erythroid cells by high-performance liquid chromatography-electrochemical detection. J Chromatogr B Biomed Sci Appl 705: 193-201, 1998.
41. Tanaka T, Satoh T, Onozawa Y, Kohroki J, Itoh N, Ishidate M Jr, Muto N and Tanaka K: Apoptosis during iron chelator-induced differentiation in F9 embryonal carcinoma cells. Cell Biol Int 23: 541-550, 1999
42. Edelman MJ, Bauer K, Khanwani S, Tait N, Trepel J, Karp J, Nemieboka N, Chung EJ and Van Echo D: Clinical and pharmacologic study of tributyrin: an oral butyrate prodrug. Cancer Chemother Pharmacol 51: 439-444, 2003.
43. Gordi T and Lepist EI: Artemisinin derivatives: toxic for laboratory animals, safe for humans? Toxicol Lett 147: 99-107, 2004.
44. Canani RB, Terrin G, Cirillo P, Castaldo G, Salvatore F, Cardillo G, Coruzzo A and Troncone R: Butyrate as an effective treatment of congenital chloride diarrhea. Gastroenterology 127: 630-634, 2004.
45. Teja-Isavadharm P, Watt G, Eamsila C, Jongsakul K, Li Q, Keeratithakul G, Sirisopana N, Luesutthiviboon L, Brewer TG and Kyle DE: Comparative pharmacokinetics and effect kinetics of orally administered artesunate in healthy volunteers and patients with uncomplicated falciparum malaria. Am J Trop Med Hyg 65: 717-721, 2001.
46. Egorin MJ, Yuan ZM, Sentz DL, Plaisance K and Eiseman JL: Plasma pharmacokinetics of butyrate after intravenous administration of sodium butyrate or oral administration of tributyrin or sodium butyrate to mice and rats. Cancer Chemother Pharmacol 43: 445-453, 1999.